News
4d
MedPage Today on MSNWin for Added Relacorilant in Platinum-Resistant Ovarian CancerOlawaiye noted that the combination is a "well-tolerated regimen and we believe it should be a new standard for ...
A Danish research team has cracked the full biosynthesis of Taxol enabling cheaper and eco-friendly production in yeast.
Taxol®, the trade name for a chemical called paclitaxel first discovered in 1967 in the bark of a yew tree, is a highly successful drug used to treat ovarian, breast, lung, liver, and other ...
With drug-coated balloons, paclitaxel’s ability to stick around in the tissue ... versus paclitaxel-coated balloon and to confirm the absence (or presence) of a class effect in DCBs.” Bernardo Cortese ...
Nearly 40% had diabetes, 17% had renal failure/impairment, and 26% had chronic limb-threatening ischemia (CLTI; Rutherford class ... that paclitaxel DCBs have progressed with each generation and have ...
The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.
and I believe utilization of this class of technology will continue to grow and evolve over time as the science is expanding. In a field largely reliant on paclitaxel drug-coated balloons ...
13d
Zacks Investment Research on MSNGILD Announces Positive Data on Trodelvy in First-Line Breast CancerGilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...
Musculoskeletal - Muscle and joint pain. Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor positive breast cancer.
After more than four years of scientific review, the FDA is rolling back warnings over cardiovascular devices and implants coated with the drug paclitaxel, saying studies have shown they do not ...
Virtue SAB to the Boston Scientific AGENT paclitaxel-coated balloon, currently the only drug-coated balloon (“DCB”) FDA-approved for a coronary indication. Data from the Virtue Trial will be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results